
Timothy M Reynolds

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7051149/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of CA125 in clinical practice. Journal of Clinical Pathology, 2005, 58, 308-312.	1.0	230
2	Relationship between Serum Copper, Ceruloplasmin, and Non–Ceruloplasmin-Bound Copper in Routine Clinical Practice. Clinical Chemistry, 2005, 51, 1558-1559.	1.5	111
3	Urinary tract pathogens and resistance pattern. Journal of Clinical Pathology, 2010, 63, 652-654.	1.0	75
4	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al Diabetes Care, 2004, 27, 2569-2569.	4.3	65
5	An investigation into the use of serum albumin in pressure sore prediction. Journal of Advanced Nursing, 2000, 32, 359-365.	1.5	61
6	Randomized Clinical Trial Comparing 2 Support Surfaces. Advances in Skin and Wound Care, 2003, 16, 317-327.	0.5	53
7	Preoperative Axillary Staging in Breast CancerSaving Time and Resources. Breast Journal, 2008, 14, 369-371.	0.4	48
8	Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. Journal of Clinical Pathology, 2013, 66, 918-923.	1.0	44
9	Increased frequency of delayed type hypersensitivity to metals in patients with connective tissue disease. Journal of Trace Elements in Medicine and Biology, 2015, 31, 230-236.	1.5	43
10	Development and validation of a symptom questionnaire for recording outcomes in adult lacrimal surgery. Rhinology, 2011, 49, 538-545.	0.7	43
11	Best practice in primary care pathology: review 3. Journal of Clinical Pathology, 2006, 59, 781-789.	1.0	38
12	Randomised controlled trial of two pressure-relieving systems. Journal of Wound Care, 2000, 9, 52-55.	0.5	36
13	Glycated haemoglobin (HbA 1c) monitoring. BMJ: British Medical Journal, 2006, 333, 586-588.	2.4	34
14	Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. Journal of Trace Elements in Medicine and Biology, 2008, 22, 50-53.	1.5	34
15	Accuracy of Cardiovascular Risk Estimation for Primary Prevention in Patients Without Diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2002, 9, 183-190.	3.1	33
16	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. International Journal of Clinical Practice, 2017, 71, e13032.	0.8	33
17	Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. American Journal of Cardiology, 2002, 89, 229-231.	0.7	30
18	Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis. Journal of Clinical Pathology, 2005, 58, 134-140.	1.0	30

#	Article	IF	CITATIONS
19	Sclerochoroidal calcification associated with Gitelman syndrome and calcium pyrophosphate dihydrate deposition. Journal of Clinical Pathology, 2005, 58, 1334-1335.	1.0	28
20	National Institute for Health and Clinical Excellence guidelines on preoperative tests: the use of routine preoperative tests for elective surgery. Annals of Clinical Biochemistry, 2006, 43, 13-16.	0.8	28
21	Copper:caeruloplasmin ratio. Journal of Clinical Pathology, 2006, 60, 441-442.	1.0	28
22	Hip fracture patients may be vitamin B ₆ deficient. Acta Orthopaedica, 1992, 63, 635-638.	1.4	26
23	A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 63-71.	3.1	26
24	Evaluation of four animal models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification. Urological Research, 1995, 23, 239-242.	1.5	24
25	Statin precipitated lactic acidosis?. Journal of Clinical Pathology, 2004, 57, 989-990.	1.0	24
26	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Current Medical Research and Opinion, 2004, 20, 811-818.	0.9	24
27	Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation. Annals of Clinical Biochemistry, 2010, 47, 72-77.	0.8	24
28	Relationship between Serum Alkaline Phosphatase and Pyridoxal-5′-Phosphate Levels in Hypophosphatasia. Clinical Science, 1998, 94, 203-206.	1.8	23
29	A regression analysis of the Waterlow score in pressure ulcer risk assessment. Clinical Rehabilitation, 2003, 17, 216-223.	1.0	23
30	Best practice in primary care pathology: review 6. Journal of Clinical Pathology, 2006, 60, 225-234.	1.0	23
31	Lipid lowering therapy in patients with HIV infection. Lancet, The, 1998, 352, 1782.	6.3	22
32	Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. Current Medical Research and Opinion, 2003, 19, 719-723.	0.9	22
33	Randomized comparison trial of the RIK and the Nimbus 3 mattresses. British Journal of Nursing, 2003, 12, 254-259.	0.3	22
34	The role of hospital acquired pressure ulcer in length of stay. Clinical Effectiveness in Nursing, 2004, 8, 4-10.	0.1	22
35	The triple test as a screening technique for Down syndrome: reliability and relevance. International Journal of Women's Health, 2010, 2, 83.	1.1	22
36	Adjusting copper concentrations for caeruloplasmin levels in routine clinical practice. Journal of Clinical Pathology, 2006, 59, 867-869.	1.0	21

#	Article	IF	CITATIONS
37	Interobserver Reliability and Intraobserver Reproducibility of the Fernandez Classification for Distal Radius Fractures. Journal of Hand Surgery: European Volume, 2009, 34, 483-485.	0.5	21
38	Is Clinical Pathology Accreditation worth it? A survey of CPAâ€accredited laboratories. British Journal of Clinical Governance, 2000, 5, 195-201.	0.3	20
39	Down's syndrome screening: a controversial test, with more controversy to come!. Journal of Clinical Pathology, 2000, 53, 893-898.	1.0	19
40	Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. European Journal of Preventive Cardiology, 2012, 19, 474-483.	0.8	18
41	Hemoglobin Old Dominion/Burton-upon-Trent, β143 (H21) His→Tyr, Codon 143 CAC→TAC—a Variant With Altered Oxygen Affinity That Compromises Measurement of Glycated Hemoglobin in Diabetes Mellitus: Structure, Function, and DNA Sequence. Mayo Clinic Proceedings, 1998, 73, 321-328.	1.4	17
42	The future of nutrition and wound healing. Journal of Tissue Viability, 2001, 11, 5-13.	0.9	17
43	A comparison of healing rates on two pressure-relieving systems. British Journal of Nursing, 2000, 9, 2270-2280.	0.3	16
44	Best practice in primary care pathology: review 4. Journal of Clinical Pathology, 2006, 59, 893-902.	1.0	15
45	The MDRD formula and validation. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 804-805.	0.2	14
46	Percentage non-caeruloplasmin bound copper. Clinical Biochemistry, 2007, 40, 749-750.	0.8	14
47	The copper/caeruloplasmin ratio in routine clinical practice in different laboratories. Journal of Clinical Pathology, 2009, 62, 60-63.	1.0	14
48	Serum screening for Down's syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1993, 100, 875-877.	1.1	13
49	Assessment of a prognostic biochemical indicator of nutrition and inflammation for identification of pressure ulcer risk. Journal of Clinical Pathology, 2006, 59, 308-310.	1.0	13
50	An evaluation of serum albumin and the sub-scores of the Waterlow score in pressure ulcer risk assessment. Journal of Tissue Viability, 2011, 20, 89-99.	0.9	12
51	Development and Validation of the Burton Score: A Tool for Nutritional Assessment. Journal of Tissue Viability, 1998, 8, 16-22.	0.9	11
52	Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Women's Health, 2013, 13, 8.	0.8	11
53	Identification of rare diseases by screening a population selected on the basis of routine pathology results—the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. Journal of Clinical Pathology, 2018, 71, 608-613.	1.0	11
54	Familial hyperchylomicronaemia. Lancet, The, 1996, 348, 1524.	6.3	10

#	Article	IF	CITATIONS
55	Antenatal screening for Down's syndrome. Lancet, The, 1998, 352, 1144.	6.3	10
56	Ethnicity in pressure ulcer risk assessment, with specific relation to the Pakistani ethnic minority in Burton, England. Journal of Advanced Nursing, 2002, 38, 592-597.	1.5	10
57	More on PROSPER. Lancet, The, 2003, 361, 1135-1136.	6.3	10
58	A randomised controlled trial comparing Drawtex with standard dressings for exuding wounds. Journal of Wound Care, 2004, 13, 71-74.	0.5	10
59	The number of unexpected HbA1c variants may be a greater problem in routine practice than is generally realized. Diabetic Medicine, 2004, 21, 1041-1044.	1.2	10
60	Risk assessment for prevention of morbidity and mortality: Lessons for pressure ulcer prevention. Journal of Tissue Viability, 2008, 17, 115-120.	0.9	10
61	Serum albumin in risk assessment for Clostridium difficile. Journal of Hospital Infection, 2009, 71, 378-379.	1.4	10
62	Implementing the national invasive cervical cancer audit: a local perspective. BJOC: an International Journal of Obstetrics and Gynaecology, 2010, 117, 1411-1416.	1.1	10
63	Patients with Recurrent Renal Stones Have a Physico-Chemically Altered Urinary Tamm-Horsfall Glycoprotein Profile. Annals of Clinical Biochemistry, 1996, 33, 540-544.	0.8	9
64	Thrombotic vascular events after change of statin. Lancet, The, 1999, 353, 845.	6.3	9
65	The relationship between serum copper and ceruloplasmin in routine clinical practice. International Journal of Clinical Practice, 2008, 62, 485-487.	0.8	9
66	ls a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. European Heart Journal, 2001, 22, 972.	1.0	8
67	<i>VACUTEX</i> â,,¢ capillary action dressing: a multicentre, randomized trial. British Journal of Nursing, 2001, 10, S66-S70.	0.3	8
68	Chemical pathology and the new contract for GPs. Journal of Clinical Pathology, 2004, 57, 1022-1024.	1.0	8
69	Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input. Annals of Clinical Biochemistry, 2004, 41, 464-468.	0.8	8
70	Survival prediction algorithms for COVIDâ€19 patients admitted to a UK district general hospital. International Journal of Clinical Practice, 2021, 75, e13974.	0.8	8
71	Total research productivity in a pathology discipline. Journal of Clinical Pathology, 2002, 55, 495-498.	1.0	8
72	DETECTION RATES AND FALSE POSITIVE RATES FOR DOWN'S SYNDROME SCREENING: HOW PRECISELY CAN THEY BE ESTIMATED AND WHAT FACTORS INFLUENCE THEIR VALUE?. Statistics in Medicine, 1997, 16, 1481-1495.	0.8	7

#	Article	IF	CITATIONS
73	Hemoglobin Wayne in a British Family: Identification by Electrospray Ionization/Mass Spectrometry. Clinical Chemistry, 2002, 48, 2261-2263.	1.5	7
74	Median parameters for Down's syndrome screening should be calculated using a moving time-window method. Annals of Clinical Biochemistry, 2008, 45, 567-570.	0.8	7
75	Obstetrics and gynaecology trainees' understanding of intrauterine device/system insertion. Journal of Family Planning and Reproductive Health Care, 2009, 35, 97-100.	0.9	7
76	Technical and clinical accuracy of three blood glucose meters: clinical impact assessment using error grid analysis and insulin sliding scales. Journal of Clinical Pathology, 2016, 69, 899-905.	1.0	7
77	Sitosterolaemia: a rare cause of accelerated atherosclerosis. Journal of Clinical Pathology, 2018, 71, 863.2-863.	1.0	7
78	Genetic risk scores in lipid disorders. Current Opinion in Cardiology, 2019, 34, 406-412.	0.8	7
79	Antenatal screening for Down's syndrome. Lancet, The, 1998, 352, 1145.	6.3	6
80	Haemoglobin Le Lamentin (alpha 20 (B1) His>Gln) in a British family: identification by electrospray mass spectrometry. Journal of Clinical Pathology, 1998, 51, 467-470.	1.0	6
81	Absence of nasal bone and detection of trisomy 21. Lancet, The, 2002, 359, 1344-1345.	6.3	6
82	Does activity in research correlate with visibility?. Journal of Clinical Pathology, 2004, 57, 426-427.	1.0	6
83	Evaluation of a wound dressing using different research methods. British Journal of Nursing, 2004, 13, S21-S24.	0.3	6
84	Implications of method specific creatinine adjustments on General Medical Services chronic kidney disease classification. Journal of Clinical Pathology, 2006, 60, 1048-1050.	1.0	6
85	Serum uric acid, the endothelium and hypertension: an association revisited. Journal of Human Hypertension, 2007, 21, 591-593.	1.0	6
86	Targeted versus global approaches to the management of hypercholesterolaemia. Perspectives in Public Health, 2008, 128, 248-254.	0.5	6
87	Vascular risk screening: possible or too much, too soon?. International Journal of Clinical Practice, 2009, 63, 989-996.	0.8	6
88	A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice. Drugs - Real World Outcomes, 2019, 6, 205-213.	0.7	6
89	Analytical Performance Verification of the Beckman Coulter AU5800 Clinical Chemistry Analyser Against Recognized Quality Specifications Reveals Relevance of Method Harmonization. Clinical Laboratory, 2016, 62, 57-72.	0.2	6
90	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. Lancet, The, 1996, 347, 466-469.	6.3	5

#	Article	IF	CITATIONS
91	Very low plasma copper levels do not automatically imply severe copper deficiency. Annals of Clinical Biochemistry, 2005, 42, 405-405.	0.8	5
92	Serum uric acid and new-onset hypertension: a possible therapeutic avenue?. Journal of Human Hypertension, 2014, 28, 519-520.	1.0	5
93	An update on trials of novel lipid-lowering drugs. Current Opinion in Cardiology, 2018, 33, 416-422.	0.8	5
94	Sheffield risk and treatment table for primary prevention of coronary heart disease. Lancet, The, 1996, 348, 1039-1040.	6.3	4
95	Effects of statins. Lancet, The, 2000, 356, 1195.	6.3	4
96	The use and understanding of CA125 as a tumor marker for ovarian cancer: a questionnaire-based survey. International Journal of Gynecological Cancer, 2008, 18, 439-445.	1.2	4
97	Emergency contraception: Patterns of use in community sexual health clinics. Journal of Obstetrics and Gynaecology, 2009, 29, 337-339.	0.4	4
98	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 423-433.	0.7	4
99	Is a lateral view essential in management of hip fracture?. European Journal of Radiology, 2012, 81, 3394-3396.	1.2	4
100	Demand management of weekend haematology and clinical biochemistry requests. International Journal of Clinical Practice, 2019, 73, e13297.	0.8	4
101	Identification of patients with Fabry disease using routine pathology results: PATHFINDER (eGFR) study. International Journal of Clinical Practice, 2021, 75, e13672.	0.8	4
102	Are drugs interchangeable?. Lancet, The, 2000, 355, 317.	6.3	3
103	Statins and fractures. Lancet, The, 2001, 357, 1887.	6.3	3
104	Accuracy of Cardiovascular Risk Estimation in Patients without Diabetes. Clinical Science, 2003, 104, 16P-16P.	0.0	3
105	Cardiovascular risk assessment. Lancet, The, 2005, 365, 1305-1306.	6.3	3
106	Prevalence of kidney disease and estimated GFR in routine practice. Annals of Clinical Biochemistry, 2006, 43, 84-85.	0.8	3
107	Amylase. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, M8-M9.	0.2	3
108	Sleight of hand in trial design: average behaviour is not average, not all new information is really new. International Journal of Clinical Practice, 2009, 63, 534-535.	0.8	3

#	Article	IF	CITATIONS
109	Hip fracture patients may be vitamin B6 deficient. Monthly Notices of the Royal Astronomical Society: Letters, 1992, 63, 635-638.	1.2	3
110	The ethics of antenatal screening: lessons from Canute. Clinical Biochemist Reviews, 2009, 30, 187-96.	3.3	3
111	Measurement of atherosclerosis progression. Lancet, The, 2001, 358, 329-330.	6.3	2
112	Evaluation of Down's syndrome screening population data sets by simulation: analyser-specific parameters may be superior to meta-analysis-derived parameters. International Journal of Clinical Practice, 2007, 62, 735-743.	0.8	2
113	Epidemiological Studies Are Meaningless without Proof of Long-Term Data Stability. American Journal of Medicine, 2008, 121, e7.	0.6	2
114	Giving antioxidants to infants with Down's syndrome. BMJ: British Medical Journal, 2008, 336, 568-569.	2.4	2
115	Targeting treatment using calculated cardiovascular disease risk: Effective? A shot in the dark? Or is it time to change the paradigm?. International Journal of Clinical Practice, 2009, 63, 1785-1791.	0.8	2
116	Donald Rumsfeld and point-of-care testing (POCT): the problem of unknown unknowns—venous blood and glucose oxidase-based test strips. Journal of Clinical Pathology, 2016, 69, 839-840.	1.0	2
117	Differential diagnosis for chronic hypokalaemia. BMJ Case Reports, 2018, 2018, bcr-2017-223680.	0.2	2
118	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. International Journal of Clinical Practice, 2018, 72, e13242.	0.8	2
119	Identification of patients with Pomp $ ilde{A}$ © disease using routine pathology results: PATHFINDER (creatine) Tj ETQq	1 1.0,784 1.0	314 rgBT /Ove
120	Screening for patients with Gaucher's disease using routine pathology results: PATHFINDER (ferritin,) Tj ETQq0 0	0 rgBT /C	overlock 10 Tf
121	Preventing pressure sores. BMJ: British Medical Journal, 2000, 320, 801-801.	2.4	2
122	Vitamin B6 Deficiency May Also Be Important. Clinical Chemistry, 1998, 44, 2555-2556.	1.5	1
123	Screening for cardiovascular disease. European Heart Journal, 2004, 25, 996.	1.0	1
124	The casino of life. Journal of Clinical Pathology, 2004, 57, 243-244.	1.0	1
125	Cost utility of prenatal diagnosis. Lancet, The, 2004, 363, 1165.	6.3	1
126	Using image analysis to determine cause, severity, status and healing prognosis in wound management. Journal of Wound Care, 2005, 14, 433-436.	0.5	1

#	Article	IF	CITATIONS
127	Down's syndrome screening: population statistic dependency of screening performance. Clinical Chemistry and Laboratory Medicine, 2008, 46, 639-47.	1.4	1
128	Inflammatory markers. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, M68-M70.	0.2	1
129	Computational models and neural nets: Fantastic models—Where to find them and how to identify them. International Journal of Clinical Practice, 2019, 73, e13391.	0.8	1
130	Primum non nocere: Demand management in pathology and preventing harm. International Journal of Clinical Practice, 2019, 73, e13311.	0.8	1
131	HEATSTROKE AND ARMY TRAINING. Lancet, The, 1988, 331, 1222.	6.3	Ο
132	Serendipity and Glycated Haemoglobin Assay: Discovery of a New Haemoglobin Variant. Annals of Clinical Biochemistry, 1995, 32, 513-513.	0.8	0
133	Swabaholics?. Lancet, The, 1995, 346, 256.	6.3	0
134	Time for SI units. Lancet, The, 1998, 352, 152.	6.3	0
135	Does Evidence-Based Medicine Provide Evidence? The Evidence on Breast Cancer and the Safety of Oral Contraceptives Suggests that Unorthodox Interpretations may be just as Valid. Breast Journal, 2003, 9, 66-67.	0.4	Ο
136	Accuracy of Cardiovascular Risk Estimation. Clinical Chemistry, 2003, 49, 706-707.	1.5	0
137	A new approach to managing prostate cancer is essential. Lancet Oncology, The, 2004, 5, 205.	5.1	0
138	Can we manage demand for allergy testing by restricting requests to a small number of prime target allergens?. Annals of Clinical Biochemistry, 2007, 44, 467-470.	0.8	0
139	Care coordination for patients with chronic conditions did not reduce hospitalizations or Medicare costs. Annals of Internal Medicine, 2009, 150, JC6.	2.0	0
140	Average serum triglyceride concentration in relation to day of the week in Burton-on-Trent. Journal of Clinical Pathology, 2009, 62, 671-672.	1.0	0
141	Care coordination for patients with chronic conditions did not reduce hospital admissions or Medicare costs. Evidence-Based Medicine, 2009, 14, 123-123.	0.6	0
142	A lifestyle intervention improved obstructive sleep apnea more than support and education in obese patients with diabetes. Annals of Internal Medicine, 2010, 152, JC1.	2.0	0
143	Is it effective to target treatment using just calculated CHD risk?. The Prescriber, 2010, 21, 24-29.	0.1	0
144	Is DHAS related to hypertension? Perhaps, but it is still impossible to be certain. Journal of Human Hypertension, 2011, 25, 405-406.	1.0	0

#	Article	IF	CITATIONS
145	Secondary tests for stratification of risk for atherosclerosis. Current Medical Research and Opinion, 2013, 29, 597-599.	0.9	0
146	Targeted lipid treatment: decades of failure suggest new targets are in order. International Journal of Clinical Practice, 2013, 67, 1214-1216.	0.8	0
147	Review of referral criteria to lipid clinics and outcomes of treatment in 4 UK centres. Atherosclerosis, 2018, 275, e239.	0.4	0
148	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: Lipid clinic experience in 2 contrasting UK centres. Atherosclerosis, 2018, 275, e100.	0.4	0
149	An audit of research productivity in clinical biochemistry revisited. JRSM Open, 2019, 10, 205427041984418.	0.2	0
150	Full treatment of the costs and benefits is needed. BMJ: British Medical Journal, 1996, 313, 1143-1143.	2.4	0
151	Pain evaluation in preterm infants using skin conductance algesimeter. Medical Research Archives, 2015, 2, .	0.1	0
152	Hemoglobin Wayne in a British family: identification by electrospray ionization/mass spectrometry. Clinical Chemistry, 2002, 48, 2261-3.	1.5	0
153	Use of coronary calcification scores to predict coronary heart disease. JAMA - Journal of the American Medical Association 2004, 291, 1831; author reply 1832-3	3.8	0